· AI Masses is the latest artificial intelligence (AI) powered analysis technology from Zoetis, delivering fast, accurate1,2 in-clinic screening of common lymph node and skin/subcutaneous lesions in minutes.
· The new capability makes Vetscan Imagyst the most capable veterinary AI analyzer in the world. †
· AI Masses will be showcased at the 40th World Veterinary Association Congress (WVAC) in conjunction with the AVMA Convention 2025 in Washington, D.C., July 18-22.
PARSIPPANY, N.J. – June 2, 2025 – Zoetis Inc., the world’s leading animal health company, has launched AI Masses, the newest addition to the Vetscan Imagyst® analyzer. AI Masses detects potentially neoplastic cells with accuracy1,2, supporting veterinary professionals to make informed decisions – streamlining diagnoses and clinic workflows. The newest indication enhances Zoetis’ digital cytology offering by enabling fast, accurate1,2 AI analysis of lymph node and skin/subcutaneous masses, delivering results in minutes. With a total of seven unique testing applications, this makes Vetscan Imagyst the world’s most capable veterinary artificial intelligence (AI) analyzer.
By leveraging advanced deep learning algorithms, AI Masses identifies and classifies common skin/subcutaneous masses and lymph node lesions. These real-time insights at the point of care increase accessibility to care for pet owners and veterinary patients – helping to increase client satisfaction. For added diagnostic confidence, expert clinical pathologist reviews via Digital Cytology and Add-on Expert Review* are accessible within hours3.
Abhay Nayak, President, Global Diagnostics at Zoetis said: “By empowering veterinary teams with valuable insights into potentially cancerous cells, we are helping to reduce waiting times and alleviate stress for pet owners facing some of the most challenging moments with their beloved pets. With comprehensive digital cytology capabilities and flexible result delivery options, Vetscan Imagyst® AI Masses allows veterinary practices to make timely, individualized treatment decisions.”
Like other AI applications in the platform, it requires familiar sample preparation, streamlining processes, reducing workflow disruptions, and empowering clinics to manage cases with confidence.
In North America, the new capability will become available on all Vetscan Imagyst analyzers on June 2, 2025.
WVAC & AVMA Convention
AI Masses will be spotlighted by Zoetis at the upcoming 40th World Veterinary Association Congress, in conjunction with the AVMA Convention 2025, July 18-22, 2025, at the Walter E. Washington Convention Center in Washington, D.C.
As part of a dynamic lineup of continuing education opportunities, Cory Penn, DVM, Head of Vetscan Imagyst, Immunoassay, and Virtual Laboratory at Zoetis, and Kristin Owens, DVM, DACVP, Clinical Pathologist, Vetscan Imagyst Development, Medical Affairs at Zoetis will be holding a lunch session focusing on cytology, “From Test to Treatment: How Cytology Screening Can Improve Access to Care for Your Patients”, on Sunday, July 20 in CE Theater 2, 12:00-12:50 PM.
To view the full diagnostics portfolio, visit https://www.zoetisdiagnostics.com/us
† Vetscan Imagyst is the only commercially available analyzer on the market offering seven testing capabilities.
* Additional costs may apply.
References:
1. Zoetis Data on File. Study Report - DHXMZ-US-25-285
2. Zoetis Data on File. Study Report - DHXMZ-US-25-286
3. Data on File. TI-11711, 2024, Zoetis Inc.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, expectations regarding products and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
# # #
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2025 Zoetis Services LLC. All rights reserved. VTS-01738
Media Contact:
Nantaara Jafri
+49 160 95655301
nantaara.jafri@zoetis.com